WebReal time CRISPR Therapeutics (CRSP) stock price quote, stock graph, news & analysis. WebApr 11, 2024 · The CRISPR Therapeutics stock price gained 1.34% on the last trading day (Thursday, 6th Apr 2024), rising from $44.80 to $45.40. During the last trading day the stock fluctuated 3.83% from a day low at $44.03 to a day high of $45.71. The price has risen in 7 of the last 10 days and is up by 5.24% over the past 2 weeks.
CRISPR Therapeutics Is an Interesting
WebFind the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest CRISPR Therapeutics AG (CRSP) stock discussion in Yahoo … View the basic CRSP option chain and compare options of CRISPR … See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including … Discover historical prices for CRSP stock on Yahoo Finance. View daily, weekly or … Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene … Find out all the key statistics for CRISPR Therapeutics AG (CRSP), including … Get the detailed quarterly/annual income statement for CRISPR Therapeutics AG … See CRISPR Therapeutics AG (CRSP) Environment, Social and Governance … See the company profile for CRISPR Therapeutics AG (CRSP) including … Find out the direct holders, institutional holders and mutual fund holders for … Web22 hours ago · CRISPR jumps 15% as Cantor issues bullish view citing exa-cel approval. Swiss biotech CRISPR Therapeutics ( NASDAQ: CRSP) added ~15% on Thursday after Cantor Fitzgerald launched its coverage with ... east georgia physician mgmt
What’s Happening With CRISPR Stock? - Forbes
WebFind real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. Web18 hours ago · Cathie Wood purchased 56,942 shares of Crispr Therapeutics yesterday. Today, the gene-editing company received a price target of $72 from Cantor Fitzgerald. CRSP stock is up by over 20% year-to-date. WebMar 9, 2024 · Although all CRISPR stocks are risky, CRISPR Therapeutics is arguably less risky than most. It has a strong cash position, thanks mainly to its partnership with Vertex. culligan water butler pa